Accelerate Diagnostics to Review Second Quarter 2018 Results on August 6th
July 19 2018 - 02:30PM
Accelerate Diagnostics, Inc. announced today it will host a
conference call on Monday, August 6, 2018 to review the company’s
second quarter 2018 financial results and commercial progress.
President and Chief Executive Officer, Lawrence Mehren, joined
by Steve Reichling, Chief Financial Officer, will review financial
results at 4:15 p.m. ET.
Audio Webcast and Conference Call
Listen to an audio webcast of the call by visiting the events
section of the company’s investor relations website at ir.axdx.com.
A replay of the audio webcast will be available until August 27,
2018.
To participate in the conference call, dial +1.877.883.0383 and
enter the conference ID: 6994802
International participants may dial +1.412.902.6506. Please dial
in 10-15 minutes prior to the start of the conference. A replay of
the call will be available by telephone at +1.877.344.7529 (U.S.)
or +1.412.317.0088 (international) using access code 10120739 until
August 27, 2018.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro
diagnostics company dedicated to providing solutions for the global
challenges of sepsis, antibiotic resistance and
healthcare-associated infections. Every 3-4 seconds someone dies
from sepsis. In the United States, sepsis remains a leading cause
of death, taking more lives than HIV, breast cancer, and prostate
cancer combined. Bacteria are the most common cause of the serious
infections that lead to sepsis, and continue to develop resistance
to antibiotics. These antibiotic resistant bacteria further
complicate the treatment approach for physicians who already wait
days for lab results to determine which antibiotics are likely to
be effective against the infection.
The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit
combine several technologies aimed at reducing the time clinicians
must wait to determine the most optimal antibiotic therapy for
these infections. The FDA cleared system and kit fully automate the
sample preparation steps to report phenotypic antibiotic
susceptibility results within 7 hours direct from positive blood
cultures. Recent external studies indicate the solution offers
results 1-2 days faster than existing methods, enabling clinicians
to optimize antibiotic selection and dosage specific to the
individual patient days earlier.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and
“ACCELERATE PHENOTEST” and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products or
technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, about our projections as to
when certain key business milestones may be achieved, the potential
of our products or technology, the growth of the market, our
estimates as to the size of our market opportunity and potential
pricing, our competitive position and estimates of time reduction
to results, and our future development plans and growth strategy.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements.
Information about the risks and uncertainties faced
by Accelerate Diagnostics is contained in the section
captioned "Risk Factors" in the company's most recent Annual Report
on Form 10-K, filed with the Securities and Exchange
Commission on March 1, 2018, and in any other reports
that we file with the Securities and Exchange
Commission from time to time. The company's forward-looking
statements could be affected by general industry and market
conditions. Except as required by federal securities laws, the
company undertakes no obligation to update or revise these
forward-looking statements to reflect new events, uncertainties or
other contingencies.
Investor Inquiries:Laura Pierson, Accelerate Diagnostics, +1 520
365-3100, lpierson@axdx.com
Media Contact:Andrew Chasteen, Accelerate Diagnostics, +1 520
365-3100, achasteen@axdx.com
Source: Accelerate Diagnostics, Inc.
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2023 to Mar 2024